Description

Explore Retatrutide 10 mg prefilled pen—an investigational triple-agonist peptide (GLP‑1, GIP, glucagon) for obesity with weekly subcutaneous dosing. Phase 2 data shows up to 24% weight loss at maximum doses. Not yet approved for clinical use